ATLASInhibikase Therapeutics (IKT) earnings date: Nov 13, 2026
Inhibikase Therapeutics (IKT) reports earnings for the quarter ended Sep 30, 2026 on Fri, Nov 13, 2026, after the close. Analysts expect EPS of -$0.11.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on IKT
| Last price | $1.51 (-2.6%) |
|---|---|
| Normal 1-day range (±1σ) | ±4.1% |
| Earnings beat history | Beat the EPS estimate in 5 of the last 6 reports |
These figures come from the same calibrated model and valuation as the Inhibikase Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Inhibikase Therapeutics reports on Nov 13, 2026. One email the day before, with ATLAS’s read on Inhibikase Therapeutics. You can switch it off at any time.
Alert me before IKT reportsFree to start. Creating an account takes under a minute.
Notify me when Inhibikase Therapeutics reports
Track IKT free Add Inhibikase Therapeutics to a free ATLAS watchlist and see its next report date in one place.
IKT earnings at a glance
| Next report (confirmed) | Fri, Nov 13, 2026 |
|---|---|
| Time | After the close |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.11 |
| Last report | Oct 27, 2026 · Beat |
| Beat rate (last 6 reports) | 5 of 6 (83%) |
| Average EPS surprise | +25.4% |
| Average move around a report | ±5.2% (last 6) |
| Sector | Healthcare · Biotechnology |
Inhibikase Therapeutics earnings history: last 6 reports
Inhibikase Therapeutics last reported on Oct 27, 2026: EPS of -$0.11 against an estimate of -$0.12 (+8.3% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Oct 27, 2026 | -$0.12 | -$0.11 | +8.3% | Beat | +6.6% |
| Aug 11, 2026 | -$0.09 | -$0.11 | -22.2% | Miss | -2.4% |
| Jul 28, 2026 | $0.37 | $0.40 | +8.1% | Beat | -6.0% |
| Apr 18, 2026 | $0.39 | $0.41 | +5.1% | Beat | -8.7% |
| Mar 26, 2026 | -$0.12 | -$0.09 | +25.0% | Beat | +3.1% |
| Dec 17, 2025 | -$0.36 | $0.10 | +127.8% | Beat | +4.4% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for IKT
See the fair value, the probability range and the earnings history of Inhibikase Therapeutics on its ATLAS page.
Inhibikase Therapeutics (IKT) stock analysisPlans from €3.99 a month.
Inhibikase Therapeutics earnings: frequently asked questions
When does Inhibikase Therapeutics (IKT) report earnings?
Inhibikase Therapeutics is scheduled to report on Friday, November 13, 2026, after the close. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for IKT?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.11 per share (USD). Estimates can change before the report.
How often does IKT beat earnings estimates?
Of its last 6 reports with a recorded result, Inhibikase Therapeutics beat the EPS estimate 5 times; the average surprise was +25.4%. Past results do not predict the next one.
How much does IKT move around earnings?
Over its last 6 reports the stock moved an average of 5.2% (absolute, from the close before the report day to the close after it), and finished higher 3 of 6 times.
Did Inhibikase Therapeutics beat earnings estimates last quarter?
Inhibikase Therapeutics last reported on Oct 27, 2026: EPS of -$0.11 against an estimate of -$0.12 (+8.3% surprise), a beat.
How much does IKT usually move in a day?
On a normal trading day the ATLAS model puts IKT’s one-day range at about ±4.1%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Fri, Nov 13, 2026
Educational information, not investment advice. Disclaimer